EPTICARD VIAL 20MG | MedicScientist :: Total Health Portal

The Brand Name EPTICARD Has Generic Salt :: EPTIFIBATIDE 

EPTICARD  Is From Company UNIMARK REM. Priced :: Rs. 1980

EPTICARD have EPTIFIBATIDE is comes under Sub class Anti Platelets of  Main Class Hematological System

Main Medicine Class:: Hematological System  Sub Medicine Class :: Anti Platelets 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
EPTIFIBATIDE  INJ  Rs. 1980  VIAL
Brand Name Company / Manufacturers Strength Unit Price / VIAL
 EPTICARD  UNIMARK REM.  20MG  VIAL Rs. 1980

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From UNIMARK REM. :: EPTICARD  EPTIFIBATIDE  Hematological System Anti Platelets

Indications for Drugs ::

Myocardial infarction, Unstable angina, Angioplasty, Percutaneous coronary intervention (PCI)

Drug Dose ::

Adult: IV: Acute Coronary Syndrome • In patients with normal renal function: The recommended adult dosage is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2.0 mcg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a PCI the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. • In patients with creatinine clearance <50 mL/min: The recommended adult dosage is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, immediately followed by a continuous infusion of 1.0 mcg/kg/min. Percutaneous Coronary Intervention (PCI) • In patients with normal renal function: The recommended adult dosage is IV bolus of 180 mcg/kg administered immediately before the initiation of PCI followed by a continuous infusion of 2.0 mcg/kg/min and a second 180-mcg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. • In patients with creatinine clearance <50 mL/min: The recommended adult dose is an IV bolus of 180 mcg/kg administered immediately before the initiation of the procedure, immediately followed by a continuous infusion of 1.0 mcg/kg/min and a second 180-mcg/kg bolus administered 10 minutes after the first. In patients who undergo CABG surgery, Eptifibatide infusion should be discontinued prior to surgery. Renal impairment: Dose reduction may be needed. CrCl (ml/min) <30 Contraindicated. Contraindication ::

Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.

Drug Precautions ::

Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check APTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy. Drug Side Effects ::

Bleeding, hypotension; localised Injection site reaction; thrombocytopaenia; back pain; anaphylaxis; GI, intracranial or pulmonary haemorrhage.

Pregnancy category ::
Pregnancy category

2

Drug Mode of Action ::  

Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis.

Drug Interactions ::

Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.

 

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.